Show simple item record

dc.contributor.authorHerbst, Fabian
dc.contributor.authorFrench, Jacqueline A.
dc.contributor.authorDlugos, Dennis J.
dc.contributor.authorPeyrard, Severine
dc.contributor.authorPelov, Diana
dc.contributor.authorFranz, David N.
dc.contributor.authorLawson, John A.
dc.contributor.authorYapici, Zuhal
dc.contributor.authorIkeda, Hiroko
dc.contributor.authorPolster, Tilman
dc.contributor.authorNabbout, Rima
dc.contributor.authorCuratolo, Paolo
dc.contributor.authorVries, Petrus J.
dc.date.accessioned2021-12-10T10:31:53Z
dc.date.available2021-12-10T10:31:53Z
dc.identifier.citationFranz D. N. , Lawson J. A. , Yapici Z., Ikeda H., Polster T., Nabbout R., Curatolo P., Vries P. J. , Dlugos D. J. , Herbst F., et al., "Adjunctive everolimus therapy for tuberous sclerosis complex-associated refractory seizures: Results from the postextension phase of EXIST-3", EPILEPSIA, 2021
dc.identifier.issn0013-9580
dc.identifier.othervv_1032021
dc.identifier.otherav_45bcf862-4ff8-49be-a5c3-f35d82446303
dc.identifier.urihttp://hdl.handle.net/20.500.12627/170079
dc.identifier.urihttps://doi.org/10.1111/epi.17099
dc.description.abstractObjective Epilepsy is highly prevalent in patients with tuberous sclerosis complex (TSC). Everolimus showed higher efficacy than placebo for seizures in the primary analysis of the EXIST-3 study. Here, we present the long-term outcomes of everolimus at the end of the postextension phase (PEP; data cutoff date: October 25, 2017). Methods After completion of the extension phase, patients were invited to continue everolimus in the PEP with everolimus (targeted trough concentration = 5-15 ng/ml, investigator-judged). Efficacy assessments included changes in seizure status during the PEP collected at 12-week intervals as parent/caregiver-reported data through a structured questionnaire. Results Among 361 patients, 343 entered the extension phase and 249 entered the PEP. After 12 weeks in the PEP, 18.9% (46/244) of patients were seizure-free since the last visit of the extension phase and 64.8% (158/244) had a stable/improved seizure status. At 24 weeks, the corresponding percentages were 18.2% (42/231) and 64.5% (149/231). Among 244 patients, the response rate was 32.8% (80/244) during the 12-week maintenance period of the core phase and 63.9% (156/244) at the end of the extension phase. Of the 149 responders at the end of the extension phase, 70.5% were seizure-free or had stable/improved seizure status. Long-term efficacy data showed persistent responses were observed in 183 of 361 patients (50.7%); 63.9% of these patients had a response that lasted at least 48 weeks. The most frequent Grade 3-4 adverse events (>= 2% incidence) reported throughout the study were pneumonia, status epilepticus, seizure, stomatitis, neutropenia, and gastroenteritis. Four patients died during the study. Significance The final analysis of EXIST-3 demonstrated the sustained efficacy of everolimus as adjunctive therapy in patients with TSC-associated treatment-refractory seizures, with a tolerable safety profile.
dc.language.isoeng
dc.subjectNeurology
dc.subjectNeurology (clinical)
dc.subjectLife Sciences
dc.subjectHealth Sciences
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectNöroloji
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectKLİNİK NEUROLOJİ
dc.titleAdjunctive everolimus therapy for tuberous sclerosis complex-associated refractory seizures: Results from the postextension phase of EXIST-3
dc.typeMakale
dc.relation.journalEPILEPSIA
dc.contributor.departmentCincinnati Childrens Hosp Med Ctr , ,
dc.contributor.firstauthorID2758029


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record